Neurodegenerative Disease
Seelos Therapeutics Inc. focuses on clinical research in spinocerebellar ataxia type-3 (SCA3), a progressive neurodegenerative disorder affecting motor coordination and neurological function.
- Spinocerebellar ataxia type-3
- Adult neurological disease
- Inherited ataxia
The sponsor’s trial activity is centered on therapeutic evaluation for adults living with SCA3, with research sites distributed across multiple countries.
Movement Disorders
Its research interest extends to conditions marked by impaired balance, gait instability, and progressive loss of coordination, placing emphasis on ataxia-related motor dysfunction.
- Gait and balance impairment
- Coordination deficits
- Motor control disorders
Clinical activity in this area reflects a therapeutic focus on neurological symptoms that affect daily mobility and physical function.
Rare Disease Therapeutics
Seelos Therapeutics Inc. is engaged in research for a rare genetic disease, supporting development efforts in an area with limited treatment options and significant unmet medical need.
- Rare neurological disorders
- Genetic ataxias
- Unmet therapeutic need
This area of interest is concentrated on targeted clinical evaluation in a narrowly defined patient population.
Adult Neurology
The sponsor’s current trial work is directed toward adult patients with a hereditary neurological condition, highlighting interest in adult-onset disease management and symptom burden.
- Adult patient populations
- Hereditary neurologic disease
- Functional neurological decline
Research sites in several countries indicate an active clinical footprint for studying neurological disease in adults.
